0439 GMT - Healthcare software provider Mach7 Technologies looks well-positioned to meet its annual guidance, according to its bull at Wilsons. Analyst Shane Storey tells clients in a note that the Australia-listed company needs to sign more new accounts in its June quarter, but still forecasts 19% annual growth in full-year contracted annual recurring revenue. That's well within Mach7's guidance of 15%-25%. Mach7 is positioned to sustainably generate operating cashflow from hereon, with its cost-cutting initiatives completed in the March quarter, Storey adds. Wilsons cuts its target price by 15% to A$0.85 and keeps an overweight rating on the stock, which is up 7.8% at A$0.345. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 30, 2025 00:39 ET (04:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.